Lung Cancer

From new imaging and targeted therapies to patient journeys, 2025 highlighted key advances and personal stories in lung cancer care and awareness.

Early trial data suggest Olvi-Vec may shrink or control cancer after platinum therapy, with safety signals in small cell and non-small cell lung cancer.

The EVEREST-2 study has reported the first complete response to CAR-T cell therapy in a patient with non-small cell lung cancer.

CURE spoke with an expert about smoking-related stigmas often faced by patients with lung cancer.

Ceralasertib plus Imfinzi failed to improve overall survival versus docetaxel in a phase 3 study of previously treated non-small cell lung cancer.

The FDA has granted approval to Rybrevant Faspro, the first and only subcutaneous therapy for EGFR-mutated non-small cell lung cancer.

The FDA granted orphan drug designation to GSK’227, now known as risvutatug rezetecan, for the treatment of small-cell lung cancer.

Wendy and Larry Brooks share their journey with small cell lung cancer, emphasizing the importance of screening, as well as advocacy for patients and caregivers.

As I reflect on my lung cancer journey, I look back to the 2018 holiday season, feeling comfortable and at peace.

This guide explains how squamous cell lung cancer is diagnosed and treated at each stage to help patients talk openly with their oncology team.

In November 2025, the FDA issued multiple oncology approvals that expanded treatment access for patients with breast, lung, blood and solid tumor cancers.

This guide explains diagnosis, staging, molecular testing and treatment options for non-small cell lung cancer to help patients prepare informed questions.

CURE sat down with Dr. Daniel J. Boffa to discuss the current treatment landscape of lung cancer care in recognition of Lung Cancer Awareness Month.

Dr. Lanyi Nora Chen, sat down for a live interview with CURE, in which, she shares her advice for newly diagnosed patients with lung cancer.

Bernadette’s strength and optimism lifted me through my own cancer journey and reminded me how much one person’s compassion can change how I move through each day.

Dr. Li-Shiun Chen sat down with CURE to discuss study findings that overturn long-held assumptions about the impact of smoking cessation in cancer care.

Immunotherapies have represented a revolution in the landscape of cancer treatment — and may have a crucial partner in the form of personalized cancer vaccines.

An expert explains how minimally invasive surgery helps remove smaller lung areas with quicker recovery and improves outcomes for patients with early-stage lung cancer.

Dr. Charles M. Rudin highlights T cell engagers, antibody-drug conjugates and emerging strategies showing early benefits for small cell lung cancer.

Sac-TMT plus Keytruda improved time without cancer growth in people with advanced lung cancer whose tumors show programmed death ligand 1.

Dr. Anne Chiang explains how biomarker testing and molecular profiling personalize lung cancer treatment and compare tissue versus liquid biopsies.

The FDA accepted a new drug application for zidesamtinib for previously treated locally advanced or metastatic ROS1-positive non-small cell lung cancer.

The FDA has approved Hyrnuo for some with locally advanced or metastatic non-squamous non–small cell lung cancer with activating mutations.

The FDA approved Imdelltra after a study showed longer survival compared with chemotherapy in advanced small cell lung cancer.

Dr. Benjamin Herzberg spotlighted some of the “weird and wacky” new ideas in the field of targeted therapies for the treatment of lung cancer.